Bioplastics may be the hottest materials story of 2007. But the topic has not caught fire at a number of major companies, ranging from GE Plastics to Bayer MaterialScience. A member of the BMS management board, Ian Paterson, put the issue into perspective at the company’s recent pre-K 2007 press conference in New York City. “We use six million tons of benzene and derivatives a year,” said Paterson in response to a question from Design News. “No one can supply six million tons of bio feedstocks.” The statement followed a discussion of the growing unpredictably of the costs in the benzene chain due to lack of production capacity and the vagaries of hydrocarbons. Might that not be a reason to give sustainable resources a bigger chance? Paterson made many other points, all true. One, biopolymers will be more expensive short-term. Another: design engineers want performance improvements, and that will be the driver of Bayer R&D. And looking at the issue from a political/environmental perspective, he noted that plastics represent only 2% of all hydrocarbon use. If the issue is to reduce use of hydrocarbons, might other targets be more attractive? And lastly, he noted that Bayer has used plant feedstocks for polyols and has a promising program for developing bio materials for use in aliphatic coatings. And being a good corporate spokesman, he also noted that Bayer is taking a “long, hard look” at the issue.
All of his comments are 100% true and very defendable. However, it can’t be denied that thee is a major push to develop bioplastics in Japan for engineering applications. Leaders such as Toyota have announced ambitious plans in bioplastics. DuPont is placing a major investment bet on biofeedstocks, although for sure only a tiny trickle of that may move into engineering applications if there is no demand. And to be sure, companies such as Bayer and GE Plastics (soon to be part of SABIC) have other major environmental platforms. But still…
Materials and assembly methods on exhibit at next week's MD&M West and other co-located shows will include some materials you should see, as well as several new and improved processes. Here's a sampling of what you can expect.
The Food & Drug Administration has approved a 3D-printed, titanium, cranial/craniofacial patient-specific plate implant for use in the US. The implant is 3D printed using Arcam's electron beam melting (EBM) process.
The upcoming MD&M West and co-located shows in Anaheim next month will be host to a huge variety of technologies and special events like the Golden Mousetrap Awards. Here are five reasons for medtech professionals to attend.
Many of the new 3D printers and printing technologies in this slideshow are breaking some boundaries, whether it's build speed, new material types, density and quality of 3D-printed circuit board layers, or build volume in a hybrid printer. We also give some recent market statistics.
Focus on Fundamentals consists of 45-minute on-line classes that cover a host of technologies. You learn without leaving the comfort of your desk. All classes are taught by subject-matter experts and all are archived. So if you can't attend live, attend at your convenience.